Skip to main content

For US Healthcare Professionals

  • Important Safety Information
  • Prescribing Information
  • Medication Guide
  • Instructions for Use
  • Contact Us
    Janssen CarePath
    1-877-CarePath
    (1-877-227-3728)

    Monday to Friday
    8 AM to 8 PM ET


    Medical Information
    1-800-JANSSEN
    (1-800-526-7736)

    Monday to Friday
    9 AM to 8 PM ET

  • HCP Site
  • Patient Site

I AM A:
DERMATOLOGYRHEUMATOLOGY
  • DERMATOLOGY
  • RHEUMATOLOGY

  • MODERATE TO SEVERE PLAQUE PSORIASIS
  • ACTIVE PSORIATIC ARTHRITIS

For US Healthcare Professionals

Prescribing Information

I AM A:
DERMATOLOGYRHEUMATOLOGY
  • DERMATOLOGY
  • RHEUMATOLOGY
 
  • MODERATE TO SEVERE PLAQUE PSORIASIS
  • ACTIVE PSORIATIC ARTHRITIS
  • Important Safety Information
  • Prescribing Information
  • Medication Guide
  • Instructions for Use
  • Contact Us
    Janssen CarePath
    1-877-CarePath
    (1-877-227-3728)

    Monday to Friday
    8 AM to 8 PM ET


    Medical Information
    1-800-JANSSEN
    (1-800-526-7736)

    Monday to Friday
    9 AM to 8 PM ET

  • HCP Site
  • Patient Site

BioCoordiNATION®: INFORMATION AND RESOURCES TO HELP YOUR PATIENTS START AND STAY ON TREMFYA®

DERMATOLOGYLEARN MORE >

RHEUMATOLOGYLEARN MORE >

Jansen Immunology

IMPORTANT SAFETY INFORMATION

 

CONTRAINDICATIONS
TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections
TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

 

INDICATIONS

TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

DOSAGE AND ADMINISTRATION

TREMFYA® is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. In active psoriatic arthritis, TREMFYA® may be administered alone or in combination with a cDMARD (e.g., methotrexate).

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.

Janssen

  • Privacy Policy
  • Legal Notice
  • Register For Updates
  • Medical Information Center

© Janssen Biotech, Inc. 2021. All rights reserved.

This site is published by Janssen Biotech, Inc., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and its territories. Janssen Biotech, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and its territories.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy | Medical Information Center | Register for Updates
 

Do not sell my personal information

Last Updated August 2021.

cp-63634v5

LEAVING JANSSEN WEBSITE

You are leaving the Janssen website and connecting to a site that is not under the control of Janssen. Janssen is not responsible for the contents of any such site or any further links from such sites. Janssen is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by Janssen. You should also be aware that the linked site may be governed by its own set of Terms and Conditions and Privacy Policy for which Janssen has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of TREMFYA® (guselkumab) or Janssen.

Do you want to leave this site?

CONTINUE